8-K: Tyra Biosciences Reports Q1 2026 Results, Advances Dabogratinib Strategy

Tyra Biosciences announced first quarter 2026 financial results, highlighting progress in its dabogratinib clinical programs and a strong cash position extending runway into late 2028.

Summary

• Tyra Biosciences reported its financial results for the first quarter ended March 31, 2026.
• The company advanced its dabogratinib 3x3 strategy, focusing on three potential pivotal studies in Low Grade Upper Tract Urothelial Carcinoma (LG-UTUC), Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), and Achondroplasia (ACH).
• The first patient was dosed in the SURF303 Phase 2a/b study for LG-UTUC, with initial results anticipated in 2027.
• Initial Phase 2 data from the SURF302 study for IR NMIBC, with over 20 patients enrolled, is expected in August 2026.
• Initial results from the safety sentinel cohort of the BEACH301 Phase 2 study for ACH are expected in Q4 2026.
• As of March 31, 2026, the company held $383.5 million in cash, cash equivalents, and marketable securities, providing an expected runway into the second half of 2028.
• Research and Development (R&D) expenses increased to $33.5 million from $25.0 million in Q1 2025, primarily due to dabogratinib development.
• General and Administrative (G&A) expenses rose to $8.5 million from $6.9 million in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant clinical progress and a strong cash position, despite an expected increase in net loss and R&D expenses.

Positives

• Strong cash position of $383.5 million as of March 31, 2026, providing runway into the second half of 2028.
• Dosing of the first patient in the potentially registrational SURF303 study for LG-UTUC.
• Over 20 patients enrolled in the SURF302 study for IR NMIBC, with data expected in August 2026.
• Successful clearance of the fourth dose level in the BEACH301 safety sentinel cohort for ACH, with initial results expected in Q4 2026.
• Appointment of Habib Dable, an experienced biopharmaceutical executive, to the Board of Directors.
• Received $147.9 million in net proceeds from the utilization of the at-the-market offering program.

Negatives

• Net loss increased to $39.3 million in Q1 2026 from $28.1 million in Q1 2025.
• Research and Development expenses increased to $33.5 million from $25.0 million year-over-year.
• General and Administrative expenses increased to $8.5 million from $6.9 million year-over-year.

Risks

• Initial or interim clinical trial results may not be indicative of final results and could materially change.
• Unconfirmed responses in clinical trials may not ultimately result in confirmed responses after follow-up.
• The novel and unproven nature of the SNP platform may not lead to successful product candidates or commercially valuable products.
• Potential delays in commencement, recruitment, enrollment, data readouts, and completion of studies and trials.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• Dependence on third parties for manufacturing, research, and preclinical testing.
• Potential for unexpected adverse side effects or inadequate efficacy of product candidates.
• Competitor developments could negatively impact programs and prospects.

Future Outlook

The company expects multiple clinical data readouts in 2026, including initial Phase 2 data from SURF302 in August 2026 and initial results from the BEACH301 safety sentinel cohort in Q4 2026. Initial results from the SURF303 study are anticipated in 2027. The company's cash position is expected to fund operations into the second half of 2028.

Management Comments

• "Our dabogratinib 3x3 strategy continues to advance with steady progress across all three programs. We are taking a differentiated, data-driven approach by aligning our development strategy with the patient journey in FGFR3-driven diseases and conditions."
• "The dosing of the first patient in SURF303 marks an important milestone, as we initiate a potentially registrational study in LG-UTUC that could support TYRA's first NDA submission."
• "With multiple clinical data readouts expected this year, we remain focused on unlocking the full potential of selective FGFR3 inhibition with oral dabogratinib."
• "In urologic cancers, we see a significant opportunity to address what we believe is a very challenging treatment paradigm for patients that is currently dominated by procedure-based, intravesical therapies. We are developing dabogratinib as a once-daily (QD) oral therapy designed to maintain continuous pressure on the tumor and, if successful, may represent a meaningful shift in how these patients are treated."
• "In achondroplasia, we believe our approach with oral dabogratinib may also be transformational. Recently presented data demonstrate that prenatal dosing further delayed premature fusion of synchondroses and increased the area of the foramen magnum. These data expand our perspective on the potential benefits of earlier FGFR3 inhibition as we advance BEACH301."

Industry Context

StockSavvy.ai notes that Tyra Biosciences is operating in the competitive clinical-stage biotechnology sector, focusing on precision medicine for FGFR biology. The company's strategy of advancing multiple FGFR3-targeted programs, particularly dabogratinib, aligns with the industry trend towards targeted therapies for specific genetic drivers of disease. The reported progress and upcoming data readouts are critical for demonstrating the potential of their platform and drug candidates in indications with significant unmet needs.

Comparison to Industry Standards

• The company's cash runway into 2H 2028 is a positive indicator, suggesting sufficient funding for ongoing clinical development compared to many early-stage biotech firms that often face funding challenges.
• The progression of dabogratinib into Phase 2 studies for LG-UTUC, IR NMIBC, and ACH reflects a typical development pathway for novel oncology and rare disease therapeutics.
• The increased R&D spend is consistent with companies advancing multiple clinical programs, a common characteristic of biotech firms in mid-stage development.
• The net loss is also typical for clinical-stage biotechs, which prioritize pipeline advancement over immediate profitability.

Management Changes

Stakeholder Impact

• Shareholders: The company's strong cash position and progress in clinical trials are positive indicators for future value creation, though increased net loss may be a concern.
• Employees: Increased R&D and G&A expenses suggest continued investment in personnel and operations, potentially leading to growth.
• Patients: Advancement of dabogratinib in urologic cancers and achondroplasia offers potential new treatment options for challenging conditions.

Next Steps

• Report initial three-month complete response data from SURF302 in August 2026.
• Report initial results from the safety sentinel cohort of BEACH301 in Q4 2026.
• Report initial results from SURF303 in 2027.
• Continue advancing the dabogratinib 3x3 strategy across LG-UTUC, IR NMIBC, and ACH indications.

Key Dates

Recommendation

The company is making steady progress in its clinical pipeline with a strong cash runway, but the increased net loss and the inherent risks of drug development warrant a cautious 'hold' recommendation until more definitive clinical data emerges.

Keywords

Tyra Biosciences, Dabogratinib, FGFR biology, LG-UTUC, IR NMIBC, Achondroplasia, Biotechnology, Clinical Trials